{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=11&state=Virginia", "query": { "state": "Virginia", "city": "Fairfax", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2551, "total_pages": 256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=12&state=Virginia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fairfax&page=10&state=Virginia&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T11:37:51.142Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Breast Cancer", "Ovarian Cancer", "Prostate Cancer", "Endometrial Cancer", "Colorectal Cancer", "Head and Neck Cancers", "Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "NSCLC" ], "interventions": [ { "name": "IDE-161", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2023-04-18", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05787587" }, { "nct_id": "NCT00760916", "title": "FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "UT-15C 1 mg", "type": "DRUG" }, { "name": "UT-15C 0.25 mg", "type": "DRUG" }, { "name": "UT-15C 5 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2008-12", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2013-01-30", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00760916" }, { "nct_id": "NCT02200614", "title": "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Non-Metastatic", "Castration-Resistant" ], "interventions": [ { "name": "Darolutamide (Nubeqa, BAY1841788)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1509, "start_date": "2014-09-12", "completion_date": "2021-06-14", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 55, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200614" }, { "nct_id": "NCT00499616", "title": "Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "12 Years", "sex": "ALL", "summary": "Up to 12 Years" }, "enrollment_count": 464, "start_date": "2007-10-08", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 166, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499616" }, { "nct_id": "NCT07321106", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Cancer (CRC)", "Colorectal (Colon or Rectal) Cancer", "CRC", "Metastatic Colon Cancer", "Colon Cancer", "Advanced Colorectal Cancer" ], "interventions": [ { "name": "CBI-1214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cartography Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-15", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321106" }, { "nct_id": "NCT00379340", "title": "Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Kidney Wilms Tumor", "Stage IV Kidney Wilms Tumor" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine Sulfate Liposome", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 395, "start_date": "2007-04-30", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 199, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379340" }, { "nct_id": "NCT00002160", "title": "A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Cancer", "Pain" ], "interventions": [ { "name": "Ziconotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002160" }, { "nct_id": "NCT03854227", "title": "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "PF-06939999 dose escalation", "type": "DRUG" }, { "name": "PF-06939999 monotherapy", "type": "DRUG" }, { "name": "PF-06939999 in combination with docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-03-14", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854227" }, { "nct_id": "NCT07408089", "title": "Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer" ], "interventions": [ { "name": "BBI-940", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boundless Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2026-02-25", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 8, "location_summary": "Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lake Success", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07408089" }, { "nct_id": "NCT06056791", "title": "Study of INKmune in Patients With mCRPC (CaRe Prostate)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Metastatic Castration-resistant Prostate Cancer", "mCRPC" ], "interventions": [ { "name": "INKmune", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inmune Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 12, "start_date": "2023-11-30", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-21T11:37:51.142Z", "location_count": 8, "location_summary": "Los Angeles, California • Las Vegas, Nevada • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056791" } ] }